SCHEDULE: Armistice Capital Boosts Ekso Bionics Stake to 9.99%

Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 9.99% of Ekso Bionics Holdings, Inc. common stock as of June 30, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 289,876 shares of Ekso Bionics Holdings, Inc. common stock.
• This ownership represents 9.99% of the total outstanding common stock of Ekso Bionics Holdings, Inc.
• The reporting persons hold shared voting power and shared dispositive power over all 289,876 shares.
• The filing is an Amendment No. 3 to a Schedule 13G, indicating an update to a previously reported ownership stake.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine beneficial ownership disclosure and does not contain performance or strategic updates.

Positives

• A significant institutional investor, Armistice Capital, maintains a substantial stake in the company, potentially signaling continued confidence in its long-term prospects.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, which could limit potential activist investor actions.

Future Outlook

This filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reflects an institutional investor's continued significant stake in Ekso Bionics Holdings, Inc., a company operating in the bionics and medical device industry. Such ownership disclosures provide transparency on major investor positions within the sector.

Related Party Transactions

• Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

Stakeholder Impact

• Shareholders gain transparency regarding the significant ownership stake held by Armistice Capital, LLC and Steven Boyd, which can influence market perception and trading activity.

Key Dates

Keywords

Ekso Bionics, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Investment Management